APOE and AβPP gene variation in cortical and cerebrovascular amyloid-β pathology and alzheimer's disease: A population-based analysis

Journal of Alzheimer's Disease

Volumn 26, Issue 2, 2011, Pages 377-385

  Peuralinna, Terhi ^a,b   Tanskanen, Maarit ^c   Mäkelä, Mira ^c   Polvikoski, Tuomo ^d   Paetau, Anders ^c   Kalimo, Hannu ^c   Sulkava, Raimo ^e   Hardy, John ^f   Lai, Shiao Lin ^g   Arepalli, Sampath ^g   Hernandez, Dena ^g   Traynor, Bryan J ^f   Singleton, Andrew ^g   Tienari, Pentti J ^a,h   Myllykangas, Liisa ^b,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FOLKHÄLSAN INSTITUTE OF GENETICS   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g NATIONAL INSTITUTE ON AGING   (United States)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; amyloid deposition; APOE; A PP; cerebral amyloid angiopathy; neuropathology

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEUROPATHOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VASCULAR AMYLOIDOSIS;

EID: 80052806558     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-102049     Document Type: Article

References (47)

1. Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD (1993) Apolipopro-tein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 90, 1977-1981. (Pubitemid 23069980)
2. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K (1995) Apolipoprotein E Dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333, 1242-1247.
3. Yamada M (2002) Risk factors for cerebral amyloid angiopathy in the elderly. Ann N Y Acad Sci 977, 37-44. (Pubitemid 35418135)
4. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Pass-more PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dich-gans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variantsat CLU and PICALM associated with Alzheimer's disease. Nat Genet 41, 1088-1093.
5. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tav-ernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, European Alzheimer, rsquo, s Disease Initiative Investigators, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41, 1094-1099.
6. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Maz-zoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A, Falcone C, Gobbi M, Colombo L, Bastone A, Beeg M, Man-zoni C, Francescucci B, Spagnoli A, Cantu L, Del Favero E, Levy E, Salmona M, Tagliavini F (2009) A recessive mutation in the APP gene with dominant-negative effect on amyloido-genesis. Science 323, 1473-1477.
7. Goate A, Chartier-Harlin M, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706. (Pubitemid 21912142)
8. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356. (Pubitemid 34790756)
9. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocam-pal long-term potentiation in vivo. Nature 416, 535-539. (Pubitemid 34288854)
10. Olson MI, Shaw CM (1969) Presenile dementia and Alzheimer's disease in mongolism. Brain 92, 147-156.
11. Sleegers K, Brouwers N, Gijselinck I, Theuns J, Goossens D, Wauters J, Del-Favero J, Cruts M, van Duijn C, Van Broeck-hoven C (2006) APP duplication is sufficient to cause early onset Alzheimer's dementia with cerebral amyloid angiopathy. Brain 129, 2977-2983. (Pubitemid 44684518)
12. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerriere A, Vital A, Dumanchin C, Feuillette S, Brice A, Vercelletto M, Dubas F, Frebourg T, Campion D (2006) App locus duplication causes autosomal dominant early-onset alzheimer disease with cerebral amyloid angiopathy. Nat Genet 38, 24-26. (Pubitemid 43011878)
13. Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL (1989) Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med 320, 1446-1452. (Pubitemid 19143709)
14. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC (1998) Molecular mapping of Alzheimer-type dementia in Down's syndrome. Ann Neurol 43, 380-383. (Pubitemid 28113601)
15. Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Fran-gione B (1990) Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126.
16. Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Ros-tagno A, Ghiso J (2009) Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol 118, 115-130.
17. Wavrant-De Vrieze F, Crook R, Holmans P, Kehoe P, Owen MJ, Williams J, Roehl K, Laliiri DK, Shears S, Booth J, Wu W, Goate A, Chartier-Harlin MC, Hardy J, Perez-Tur J (1999) Genetic variabilityatthe amyloid-beta precursor protein locus may contribute to the risk of late-onset Alzheimer's disease. Neurosci Lett 269, 67-70. (Pubitemid 29335414)
18. Athan E, Lee J, Arriaga A, Mayeux R, Tycko B (2002) Poly-morphismsinthe promoterofthe human APP gene:functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol 59, 1793-1799. (Pubitemid 35340491)
19. Heston LL, Orr HT, Rich SS, White JA (1991) Linkage of an Alzheimer disease susceptibility locus to markers on human chromosome 21. Am J Med Genet 40, 449-453.
20. Guyant-Marechal L, Rovelet-Lecrux A, Goumidi L, Cousin E, Hannequin D, Raux G, Penet C, Ricard S, Mace S, Amouyel P, Deleuze J, Frebourg T, Brice A, Lambert J, Campion D (2007) Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology 68, 684-687. (Pubitemid 46667816)
21. Lahiri D, Ge Y, Maloney B, Wavrant-De Vrieze F, Hardy J (2005) Characterization of two APP gene promoter polymorphisms that appear to influence risk of late-onset alzheimer's disease. Neurobiol Aging 26, 1329-1341. (Pubitemid 41483761)
22. Lv H, Jia L, Jia J (2008) Promoter polymorphisms which modulate APP expression may increase susceptibility to alzheimer's disease. Neurobiol Aging 29, 194-202.
23. Theuns J, Brouwers N, Engelborghs S, Sleegers K, Bogaerts V, Corsmit E, De Pooter T, van Duijn C, De Deyn P, Van Broeckhoven C (2006) Promoter mutations that increase amyloid precursor-protein expression are associated with alzheimer disease. Am J Hum Genet 78, 936-946. (Pubitemid 43787686)
24. Nowotny P, Simcock X, Bertelsen S, Hinrichs A, Kauwe J, Mayo K, Smemo S, Morris J, Goate A (2007) Association studies testing for risk for late-onset Alzheimer's disease with common variants in the beta-amyloid precursor protein (APP). Am J Med Genet B Neuropsychiatr Genet 144, 469-474. (Pubitemid 46983157)
25. Myllykangas L, Polvikoski T, Reunanen K, Wavrant-De Vrieze F, Ellis C, Hernandez D, Sulkava R, Kontula K, Verkkoniemi A, Notkola I, Hardy J, Perez-Tur J, Haltia M, Tienari P (2002) ApoE epsilon3-haplotype modulates Alzheimer beta-amyloid deposition in the brain. Am J Med Genet 114, 288-291. (Pubitemid 34258853)
26. Tanskanen M, Lindsberg PJ, Tienari PJ, Polvikoski T, Sulkava R, Verkkoniemi A, Rastas S, Paetau A, Kiuru-Enari S (2005) Cerebral amyloid angiopathy in a 95 + cohort: complement activation and apolipoprotein E (ApoE) genotype. Neuropathol Appl Neurobiol 31, 589-599. (Pubitemid 41668368)
27. Litchfield S, Nagy Z (2001) New temperature modification makes the Bielschowsky silver stain reproducible. Acta Neu-ropathol 101, 17-21. (Pubitemid 32124495)
28. Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K (1990) Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol 79, 569-572. (Pubitemid 20095419)
29. Polvikoski T, Sulkava R, Myllykangas L, Notkola IL, Niinisto L, Verkkoniemi A, Kainulainen K, Kontula K, Perez-Tur J, Hardy J, Haltia M (2001) Prevalence of Alzheimer's disease in very elderly people: a prospective neuropathological study. Neurology 56, 1690-1696. (Pubitemid 32574568)
30. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486.
31. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
32. Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Crook R, Tienari PJ, Pusa AK, Niinisto L, O'Brien P, Kontula K, Hardy J, Haltia M, Perez-Tur J (1999) Genetic association of alpha2-macroglobulin with Alzheimer's disease in a Finnish elderly population. Ann Neurol 46, 382-390. (Pubitemid 29416276)
33. Brouwers N, Sleegers K, Engelborghs S, Bogaerts V, Serneels S, Kamali K, Corsmit E, De Leenheir E, Martin J, De Deyn P, Van Broeckhoven C, Theuns J (2006) Genetic risk and transcriptional variability of amyloid precursor protein in alzheimer's disease. Brain 129, 2984-2991. (Pubitemid 44684519)
34. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559-575. (Pubitemid 47330214)
35. Barrett J, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263-265. (Pubitemid 40202029)
36. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blu-menstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D (2002) The structure of hap-lotype blocks in the human genome. Science 296, 2225-2229. (Pubitemid 34680308)
37. Peuralinna T, Oinas M, Polvikoski T, Paetau A, Sulkava R, Niinisto L, Kalimo H, Hernandez D, Hardy J, Singleton A, Tienari PJ, Myllykangas L (2008) Neurofibrillary tau pathology modulated by genetic variation of alpha-synuclein. Ann Neurol 64, 348-352.
38. Taillon-Miller P, Bauer-Sardina I, Saccone NL, Putzel J, Laiti-nen T, Cao A, Kere J, Pilia G, Rice JP, Kwok PY (2000) Juxtaposed regions of extensive and minimal linkage disequilibrium in human Xq25 and Xq28. Nat Genet 25, 324-328. (Pubitemid 30437322)
39. Peltonen L, Palotie A, Lange K (2000) Use of population isolates for mapping complex traits. Nat Rev Genet 1, 182-190.
40. Shifman S, Darvasi A (2001) The value of isolated populations. Nat Genet 28, 309-310.
41. Zaccai J, Ince P, Brayne C (2006) Population-based neu-ropathological studies of dementia: design, methods and areas of investigation-a systematic review. BMC Neuro 9, 2.
42. Nicoll JA, Savva GM, Stewart J, Matthews FE, Brayne C, Ince P (2011) Association between APOE genotype, neuropathol-ogy and dementia in the older population of England and Wales. Neuropathol Appl Neurobiol 37, 285-294.
43. Kalaria RN (1997) Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease. Ann N Y Acad Sci 826, 263-271. (Pubitemid 27478048)
44. Weller RO, Yow HY, Preston SD, Mazanti I, Nicoll JA (2002) Cerebrovascular disease is a major factor in the failure of elimination of Abeta from the aging human brain: implications for therapy of Alzheimer's disease. Ann N Y Acad Sci 977, 162-168. (Pubitemid 35418150)
45. Streit WJ, Braak H, Xue QS, Bechmann I (2009) Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 118, 475-485.
46. Deane R, Bell RD, Sagare A, Zlokovic BV (2009) Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease. CNS Neurol Disord Drug Targets 8, 16-30.
47. Agostinho P, Cunha RA, Oliveira C (2010) Neuroinflamma-tion, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 16, 2766-2778.